A Medication study for Children with Major Depressive Disorder (Ages 7 -17)

Official Title: A Double-blind, Placebo- and Active-controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Pediatric Patients 7-17 Years With Major Depressive Disorder


The purpose of this research study is to evaluate the drug Levomilnacipran extended-release to see how well the drug works, observe the side effects, and how well tolerated it is compared to placebo in pediatric patients with major depressive disorder.

Eligibility criteria:

Your child may be eligible if:
• be between 7 and 17 years of age
• give their assent (a simplified version of this consent form that your child will sign)
• have a diagnosis of Major Depressive Disorder
• meet all of the additional relevant inclusion criteria
• understand the study instructions, and be willing and able to follow these instructions

Exclusion Criteria:
• Your child will not be able to take part in the study if she is pregnant, nursing, or planning a pregnancy
• Your child will not be able to take part in this study if he/she takes any illegal substances

Contact Information

Lily Prior